|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Kidney Cancer (renal cell cancer)
Kidney cancer or renal cell cancer is the most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine. It is also called hypernephroma. [Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
“RECORD-3” Kidney Cancer Study CRAD001L2202
The reason for the study is to compare a study drug when given before Sutent® versus taking Sutent® before the study drug. We want to investigate the sequence of both drugs to see which sequence will show better results on how quickly the tumors may react, or how long before the tumor starts to grow. We also want to investigate the harmful effects of both drugs to see which treatment sequence has less side-effects for the patient.
Trial phase: Phase 2 Participation Duration: Participants will be required to visit the study center 2 times during each 42 day treatment cycle. Participation duration will last until disease progression, unacceptable toxicity, or discontinuation from treatment for any other reason. Protocol Number: CRAD001L2202 |